CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segment
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of biosimilar drugs
3.4 Key Findings
3.4.1 Top impacting factors
3.4.2 Top winning strategies
3.4.3 Top investment pockets
3.5 Regulation and Reimbursement scenario
3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines
3.6 Emerging economies a hotspot for biosimilars market
3.6.1 Brazil a treasure for the biosimilar manufacturers
3.6.2 China the bulkmarket for biosimilars
3.6.3 India an early adopter of biosimilars
3.7 Porters five force analysis
3.7.1 Higher bargaining of suppliers
3.7.2 Moderate bargaining power of buyers
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players
3.8 Value chain analysis
3.8.1 Primary activities
3.8.2 Supportive activities
3.9 Clinical trials
3.9.1 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.2 Efficacy Study of Two Formulations of Erythropoietin
3.9.3 Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.4 An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
3.10 Market Share analysis, 2014
3.11 Market Dynamics
3.11.1 Drivers
3.11.1.1 Growing pressure to reduce healthcare expenditure
3.11.1.2 Various blockbusters going off patent
3.11.1.3 High prevalence of chronic diseases among ageing population
3.11.1.4 Favorable intervention from the developing economies
3.11.1.5 Lower cost biosimilars drugs than original biologics
3.11.2 Restraints
3.11.2.1 High initial investment in research and development
3.11.2.2 Stringent regulations in developed economies to restrict investment
3.11.2.3 Medical Efficacy and Patient Safety
3.11.3 Opportunities
3.11.3.1 opportunities in Emerging economies
3.11.3.2 Emergence of bio-betters drugs
CHAPTER 4 GLOBAL MARKET BY TECHNOLOGY
4.1 Monoclonal Antibodies (MAb) Technology
4.1.1 Drivers
4.2 Recombinant DNA Technology (rDNA technology)
4.2.1 Drivers
4.2.2 Restraints & Opportunities
4.3 Chromatography
4.3.1 Protein sequencing
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Drivers
4.4 Nuclear magnetic resonance (NMR) technology
4.4.1 Drivers
4.5 Electrophoresis
4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis
4.6 MASS SPECTROMETRY
4.6.1 Drivers
4.6.2 Restraints
4.7 Western Blotting
4.7.1 Drivers
4.8 Bioassay
4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay
CHAPTER 5 GLOBAL BIOSIMILARS MARKET BY PRODUCT
5.1 Human Growth Hormone
5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size & forecast
5.2 Insulin
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size & forecast
5.3 Interferon
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size & forecast
5.4 Granulocyte colony stimulating factor (G-CSF)
5.4.1 Key market trends
5.4.2 Key growth factors and opporunities
5.4.3 Market size & forecast
5.5 Erythropoietin
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size & forecast
5.6 Monoclonal antibodies
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size & forecast
5.7 Peptides
5.8 Others
5.8.1 Key market trends
5.8.2 Key growth factors and opportunity
CHAPTER 6 GLOBAL MARKET BY APPLICATIONS
6.1 Blood disorders
6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia
6.1.2.1 Drivers
6.1.2.2 RESTRAIN AND OPPORTINITIES
6.1.3 Hemophilia
6.1.4 Pulmonary embolism
6.1.4.1 DRIVER
6.2 Oncology diseases
6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Breast cancer
6.2.5 Cervical cancer
6.2.6 Colorectal cancer
6.2.7 Prostate cancer
6.2.8 Leukaemia
6.3 Chronic and autoimmune diseases
6.3.1 Diabetes
6.3.1.1 Drivers
6.3.2 Neutropenia
6.3.3 Multiple sclerosis
6.3.3.1 Drivers
6.3.3.2 Restraints and opportunities
6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA)
6.3.5.1 Drivers
6.3.5.2 Restraints
6.3.6 Acromegaly
6.3.6.1 drivers
6.3.7 Leprosy
6.4 Growth hormone deficiency
6.4.1 Drivers
6.5 Others
6.5.1 Gaucher disease
6.5.2 Osteoporosis
CHAPTER 7 GLOBAL MARKET BY SERVICES
7.1 Contract Research and Manufacturing Services
7.1.1 Drivers
7.1.2 Restraints & Opportunities
7.2 Clinical trials
7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
CHAPTER 8 GLOBAL BIOSIMILARS MARKET BY GEOGRAPHY
8.1 North America
8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast
8.2 Europe
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast
8.3 Asia-Pacific
8.3.1 Key market trends
8.3.1.1 India
8.3.1.1.1 COMPETITIVE SCENARIO
8.3.1.2 China
8.3.1.2.1 COMPETITIVE SCENARIO
8.3.1.3 Australia
8.3.1.3.1 COMPETITIVE SCENARIO
8.3.2 Key growth factors and opporunities
8.3.3 Market size & forecast
8.4 LAMEA
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size & forecast
CHAPTER 9 KEY PRODUCTS AND RECENT ACTIVITIES
9.1 US
9.1.1 Hospira
9.1.1.1 Recent Activities
9.2 Europe
9.2.1 Stada Arzneimittel AG
9.2.1.1 Recent Activities
9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton
9.2.4.1 Recent Activities
9.2.5 Sandoz GmbH
9.2.5.1 Recent Activities
9.3 India
9.3.1 Dr.Reddy's Labs (DRL)
9.3.1.1 Recent Activities
9.3.2 Intas Pharmaceuticals Ltd.
9.3.2.1 Recent Activities
9.3.3 Wockhardt Limited
9.3.3.1 Recent Activities
9.3.4 Biocon Limited
9.3.4.1 Recent Activities
9.3.5 Shantha Biotechnics Limited
9.3.5.1 Recent Activities
9.3.6 Reliance Life Sciences
9.4 Korea
9.4.1 Dong-A Pharmaceutical Co., Ltd
9.4.1.1 Recent Activities
9.4.2 LG Life Sciences
9.4.2.1 Recent Activities
9.4.3 Celltrion Pharm, Inc.
9.4.3.1 Recent Activities
9.5 Others
9.5.1 Teva Pharmaceutical Industries Ltd.
9.5.1.1 Recent Activities
CHAPTER 10 COMPANY PROFILES
10.1 Novartis (Sandoz)
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segment overview
10.1.4 Business performance
10.1.5 Key strategies
10.1.5.1 Primary Strategies: Clinical Trials
10.1.5.2 secondary Strategies: approval
10.1.6 SWOT analysis
10.2 Synthon Pharmaceuticals, Inc.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segment overview
10.2.4 Key strategies
10.2.4.1 Primary Strategies: agreement
10.2.4.2 secondary Strategies: clinical trials
10.2.5 SWOT analysis
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Operating business segment overview
10.3.4 Business performance
10.3.5 Key strategies
10.3.5.1 Primary Strategies: approval
10.3.5.2 secondary Strategies: clinical trials
10.3.6 SWOT analysis
10.4 LG Life Sciences
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segment overview
10.4.4 Business performance
10.4.5 Key strategies
10.4.5.1 Primary Strategies: Collaboration
10.4.6 SWOT analysis
10.5 Celltrion
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segment overview
10.5.4 Business Performance
10.5.5 Key strategies
10.5.5.1 Primary Strategies: approval
10.5.6 SWOT analysis
10.6 Biocon
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segment overview
10.6.4 Business Performance
10.6.5 Key strategies
10.6.5.1 Primary Strategy: product launch
10.6.5.2 secondary Strategy: clinical trial
10.6.6 SWOT analysis
10.7 Hospira
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segment overview
10.7.4 Business performance
10.7.5 Key strategies
10.7.5.1 Primary Strategies: approval
10.7.5.2 secondary Strategies: clinical trials
10.7.6 SWOT analysis
10.8 Merck Serono (Merck Group)
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segment overview
10.8.4 Business performance
10.8.5 Key strategies
10.8.5.1 Primary Strategies: partnership and product launch
10.8.6 SWOT analysis
10.9 Biogen idec Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segment overview
10.9.4 Business performance
10.9.5 Key strategies
10.9.5.1 Primary Strategies: agreement and joint venture
10.9.6 SWOT analysis
10.10 Genentech (Roche Group)
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segment overview
10.10.4 Key strategies
10.10.4.1 Primary Strategies: Investment and license
10.10.5 SWOT analysis